The Elixir Sulfanilamide tragedy

A safe drug did not make a safe mixture

Sulfanilamide had already been used in tablets and powders to treat bacterial infections. Seeking a liquid version, the S. E. Massengill Company used diethylene glycol as the solvent.^[1] Its laboratory checked characteristics such as taste and appearance, but did not test the new formulation for toxicity.^[1] The company then distributed hundreds of shipments of the raspberry-flavoured preparation.

The distinction between drug and formulation mattered. Experience with sulfanilamide itself did not establish that a mixture containing another chemical was safe. Diethylene glycol was the poisonous ingredient.^[1][2] The resulting deaths demonstrated why the substances carrying a medicine into the body require scrutiny alongside the active ingredient.

Following the evidence and the bottles

The American Medical Association’s contemporary laboratory report records telegrams from Tulsa physicians on 11 October 1937.^[2] Six deaths had been reported following use of the preparation, with failure to produce urine a shared finding.^[2] Investigators obtained samples, requested the composition from the manufacturer and tested preparations from more than one source. Animal experiments also implicated the solvent. Reports from elsewhere showed that the problem extended beyond Tulsa.

The AMA issued a public warning on 18 October.^[2] FDA inspectors then faced a distribution problem as well as a laboratory problem: the dangerous liquid had already reached pharmacies, doctors and patients. Investigators followed shipping and sales records, sometimes finding incomplete names or addresses. Nearly the agency’s entire field force worked on recovering the product.^[1]

A recall depended on saying what was wrong

FDA’s history reports that Massengill’s first telegrams requested returns without making the lethality or urgency clear.^[1] The agency required a stronger warning. Retrieving a distributed medicine depended on more than finding shipping records: pharmacists and doctors needed enough truthful information to interrupt use immediately, including doses already supplied to patients.

A gap in the law

Federal law offered an awkward route to seizure. The product was misbranded because the term elixir implied an alcoholic preparation, whereas this mixture contained no alcohol.^[1] The FDA’s history explains that the law did not then require the safety studies that would have exposed the danger before distribution. Enforcing a naming rule was an inadequate substitute for a clear preventive safety requirement.

Reform proposals had been before Congress for years. The deaths helped break that legislative impasse, rather than creating the idea of food and drug reform from nothing. President Franklin Roosevelt signed the Federal Food, Drug, and Cosmetic Act on 25 June 1938.^[3] New drugs had to be shown safe before marketing, and the law strengthened directions for use, inspections and enforcement.^[4]

The change moved a crucial decision earlier in a medicine’s life. Under the previous approach, investigators could be forced to reconstruct harm after patients had received an untested preparation. The new requirement placed the obligation to establish safety before distribution. It did not abolish drug risk, but it changed when evidence was required and who had to produce it.